Lauroyl-gemcitabine lipid nanocapsule hydrogel for the local treatment of glioblastoma
(2018)
Files
ThèseBastiancich.pdf
Open Access - Adobe PDF
- 6.68 MB
Details
- Authors
Bastiancich, Chiara 
- Supervisors
- Abstract
- Glioblastoma (GBM) is an aggressive and incurable malignant brain tumor. Despite aggressive standard of care therapy GBM always recur, mainly because of its high invasiveness and chemoresistance. In this Thesis, we evaluate the feasibility, efficacy and safety of the nanomedicine hydrogel Lauroyl-gemcitabine lipid nanocapsule (GemC12-LNC) for the local treatment of GBM. GemC12-LNC is injectable, adapted for brain implantation and able to sustainably release the drug. In healthy mice brain the hydrogel is well tolerated. Intratumoral injection of GemC12-LNC hydrogel in different GBM models significantly reduced tumor growth. To mimic the clinical setting, a surgical resection technique was developed in mice and rats, and the perisurgical administration of GemC12-LNC reduced the formation of recurrences in both cases. In conclusion, this work showed that GemC12-LNC is a promising and innovative delivery system for the local treatment of GBM. This gel can be directly injected in the GBM resection cavity, has a very simple formulation and combines the properties of nanomedicines and hydrogels.
- Affiliations
Citations
Bastiancich, C. (2018). Lauroyl-gemcitabine lipid nanocapsule hydrogel for the local treatment of glioblastoma. https://hdl.handle.net/2078.5/56386